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Abstract
Background: The sustained growth of tumors necessitates neovascularization. As one of the
potent endogenous vascular inhibitors, endostatin has been widely used in antiangiogenesis therapy
for tumor. Cisplatin is normally administered in chemotherapy for lung cancer but accompanied
with serious side effects. In the current study, we investigated a novel chemo-antiangiogenesis
therapeutic strategy to both improve toxic effects on lung cancer cells and reduce damages to
normal cells in the anti-tumor therapy.
Methods: In vitro, we transduced LLC cells with Ad-hEndo and collected supernatants. Western
blotting analysis of the supernatants revealed expression of endostatin. In vivo, to fully investigate
the suppression effect on murine lung cancer of the combination therapy, we injected recombinant
human endostatin adenovirus intratumorally plus a low dose of cisplatin intraperitoneally routinely.
The tumor volume and survival time were observed. Angiogenesis was apparently inhibited within
the tumor tissues and on the alginate beads. Assessment of apoptotic cells by the TUNEL assay was
conducted in the tumor tissues.
Results: The combination treatment significantly suppressed the tumor growth and prolonged
survival time of the murine LLC tumor model. This anti-tumor activity was associated with
decreased microvessel density and increased apoptotic index of tumor cells.
Conclusion: According to the results in this study, recombinant human endostatin adenovirus in
combination with a low dose of cisplatin demonstrated apparent synergistic anti-tumor activity
without marked toxicity. Thus, these observations may provide a rational alternative for lung
cancer treatment.
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Background
The blood vessel formation plays an essential role in a
large variety of physiological and pathological conditions.
Numerous studies have shown that growth and progres-
sion of most solid cancers are ngiogenesis-dependent [1-
4]. Neovascularization includes multiple complex
sequential steps: degradation of basement membranes,
proliferation and migration of endothelial cells, and dep-
osition of basement membranes. Tumor angiogenesis is
strongly regulated by both positive and negative factors in
tumor growth, including a few growth factors such as
VEGF, MMPs, and bFGF that regulate proliferation, migra-
tion and adhesion of endothelial cells. One of the potent
endogenous angiogenesis inhibitors, endostatin, is a
cleavage fragment containing COOH-terminal 184 amino
acids of the basement membrane collagen XVIII. This
product inhibits endothelial cell migration and prolifera-
tion, and then induces regression of tumors[5].
The theory of antiangiogenesis has been set forth by Folk-
man and others since the 1970s. It has advocated that sup-
pressing tumor-related angiogenesis and thus depriving
tumors of supply lines (of essential nutrients and oxygen)
leads to a "dormant" state in which tumor cell prolifera-
tion and tumor expansion is stalled. In recent years, there
have been quite a few published reports showing promis-
ing efficacy of endostatin protein in both cancer research
and cancer clinical trials [6-8].
With the highest rates of morbidity and mortality among
malignant tumors, lung cancer is one of the most com-
mon types of cancer threatening public health. Chemo-
therapy has been the leading treatment for cancer for a
long time. And cisplatin is administered frequently in
chemotherapy for lung cancer. However, the conventional
chemotherapy is often accompanied by serious side
effects, such as myelosuppression, kidney toxicity and
nausea, leading to give-up of anti-tumor treatment. In the
past decade, some other new cytotoxic drugs have come
into clinic application. Despite the progress, chemother-
apy has not satisfied expectation of complete responses to
the therapy in patients or achieved cures in patients with
advanced-stage cancer, which limited its application in
clinical practice.
Besides traditional treatments such as chemotherapy, new
cancer treatment strategies have been developed in recent
years. An approach combining low-dose chemotherapy
with antiangiogenesis factors has been reported to be
potent in treatment of established animal tumors. Widely
applied to inhibit cancer angiogenesis, gene therapy, espe-
cially adenovirus gene therapy shows no disadvantages of
recombinant protein injection[9,10]. In the current
research, we evaluated efficacy of combination of recom-
binant endostatin adenovirus with a low dose of cisplatin
in treatment of murine Lewis lung cancer.
Methods
Construction of recombinant adenovirus
Construction of recombinant human endostatin adenovi-
rus has been described in the previous study[8]. In brief,
the endostatin cDNA encoding C-terminal 184 amino
acids of human collagen XVIII was amplified by RT-PCR.
After sequence confirmation, the cDNA was firstly cloned
into the cloning vector PUC18 and then into a shuttle vec-
tor for rescue of recombinant adenovirus (using the
AdEasy system). The recombinant adenovirus was con-
structed and purified in our lab.
Cell Culture and viral preparation
Human embryonic kidney cell line (HEK293) and Lewis
lung cancer cells (LLC) were obtained from the American
Type Culture Collection (ATCC). They were cultured in
DMEM supplemented with 10% fetal bovine serum (FCS)
plus 1% amikacin routinely. The cultures were split 1:3
every 4 days. The viral particles were amplified in 293
cells, purified by CsCl gradient ultracentrifugation and
measured by absorption (at A260). The virus titer was
quantified using the standard TCID50 assay.
Western Blotting of transfected cells supernatants in Vitro
LLC cells were transduced with Ad-hEndo and the control
virus, Ad-null (both at MOI 100, 108pfu per 106 cells in
1.0 ml complete medium) or involved no transduction.
After the cells were conditioned at 37°C for 48 h, super-
natants were harvested and concentrated by ultrafilter
(centricon YM-3, Millipore), and were mixed with the
same volume of 2× SDS (sodium dodecyl sulfate) sample
buffer. Samples were separated on a 12% SDS-PAGE gel
and transferred onto a PVDF membrane (polyvinylidene
difluoride, BIO-RAD). After the cells were blocked by
TTBS (0.1%Tween-20 in TBS) with 5% defatted milk for 1
h, the membrane was probed with rabbit antihuman
endostatin serum (1:100) overnight at 4°C. Later the cells
were incubated with 1:5000 horseradish peroxidase-con-
jugated anti-rabbit immunoglobulin (Sigma-Aldrich, St.
Louis, MO, US). Protein bands were visualized using the
DAB detection kit (Sigma-Aldrich, St. Louis, MO, US).
Animal experiments
Female (6–8 weeks old) C57BL/6 mice (purchased from
the Laboratory Animal Center of Sichuan University,
Chengdu, Sichuan, China) were acclimated for one week
and were fed with animal chow and water ad libitum. The
mice were anesthetized prior to all procedures and
observed until fully recovery.
The C57BL/6 mice of 6–8 weeks were injected s.c. with 1
× 106 LLC cells in 100 μl PBS in the right flank. 7 d later,Journal of Experimental & Clinical Cancer Research 2009, 28:31 http://www.jeccr.com/content/28/1/31
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when the tumors were palpable, the mice were randomly
divided into 5 groups (n = 5 animals/group): Ad-hEndo,
intratumoral injection of 1 × 109pfu/100 μl recombinant
adenovirus; cisplatin, intraperitoneal treatment of 1 mg/
kg/100 μl; Ad-hEndo plus cisplatin, Ad-hEndo delivery
locally, along with cisplatin administration intraperito-
neally; empty virus, Ad-null, intratumoral injection of 1 ×
109pfu/100  μl control virus; and NS, equal volume of
0.9% NaCl administered in the same schedule as other
groups. All the treatments were performed twice a week
and lasted for 2 wk. Tumor width (W) and length (L) were
measured every 4 d by calipers. The tumor volume (Tv)
was calculated according to the following formula: Tv =
0.52 × L × W2. The treated mice were closely monitored
and sacrificed if any signs of approaching death were
shown. The mice in all groups were sacrificed 50 days after
tumor establishment. All experiments involving mice
were approved by the Institute's Animal Care and Use
Committee.
Detection of microvessel density and apoptosis
Frozen tissues were sectioned (5 μm) and fixed in acetone
at 4°C. For detection of CD31 immunostaining, sections
were probed with a monoclonal rat anti-mouse CD31
antibody (1:400, Santa Cruz Biotechnology, Santa Cruz,
CA, US) at 4°C overnight, followed by incubation with
biotinylated polyclonal goat anti-rat antibody (1:200,
Vector Laboratories, Peterborough, UK) and Vectastain
Elite ABC Kit (Vector Laboratories, Peterborough, UK).
Positive reaction was visualized using 3,3-diaminobenzi-
dine as chromagen (DAB substrate kit, Vector Laborato-
ries, Peterborough, UK). Sections were counterstained
with hematoxylin and mounted with glass coverslips.
Apoptotic cells were identified using the TUNEL (terminal
deoxynucleotidyl transferase-mediated nick end labeling)
assay (In Situ Cell Death Detection Kit, Roche, Basel, Swit-
zerland) following the manufacturer's guide. Images were
captured by the Olympus fluorescence microscope at
×200 magnification. The quantification of microvessel
density (MVD) (the maximum vascular area of the tumor)
was assessed within hot spot[11]. The apoptotic cells were
counted in 5 high power fields in each slide in a blinded
manner. The percentage of apoptotic cells among tumor
cells were calculated as apoptotic index.
Alginate encapsulation assay
Alginate bead containing tumor cell assay was described
in details previously[8]. Briefly, cultured LLC cells were
resuspended with 1.5% (m/v) sodium alginate (Sigma-
Aldrich, St. Louis, MO, US), and then the tumor cell algi-
nate solution was dropped into a swirling bath of 0.25 M
CaCl2 in order to form droplets containing about 1 × 105
tumor cells per bead. After anesthetized, the C57BL/6
mice were implanted s.c. with four beads into an incision
on the back, the incisions were sutured with surgical
clamps. Treatment of Ad-hEndo (1 × 109pfu/100 μl) or
cisplatin (1 mg/kg) was performed on day 0, 4, 8, 12 after
bead implantation, with Ad-null or saline as control. At
14 days, the mice were injected i.v. with 100 μl FITC-dex-
tran solution (Sigma Chemical) (100 mg/kg) and were
sacrificed 20 minutes later. Image of the alginate implants
was taken by using SPOT FIEX camera. Alginate beads
were transferred to tubes containing 2 ml of saline. The
tubes were mixed by a vortex for 20 s and centrifuged (3
min; 1000 × g). Finally the fluorescence of the superna-
tant was measured to quantify blood vessel formation.
Toxicity Observation
Drug toxicity indexes such as weight loss, ruffled fur,
behavior change and feeding patterns were continuously
observed during the whole treatment.
To clarify potential side effects in the treated mice, the tis-
sues of heart, liver, spleen, lung, kidney, etc., were fixed in
4% neutral buffered paraformaldehyde solution and
embedded in paraffin. Sections of 3–5 μm were stained
with hematoxylin and eosin (HE), and observed by two
pathologists in a blinded manner.
As most adenoviruses infect liver tissues, we intratumor-
ally injected viruses at 1 × 109 p.f.u./mouse, with cisplatin
administration intraperitoneally. The operation schedule
was the same as that for the animal experiments. After
two-week treatment, blood samples were extracted from
the tail vein. The white blood cell count, red blood cell
count and platelet count were determined as measures of
bone marrow toxicity, whereas creatinine, and GOT plus
GPT were recorded as measures of kidney and liver toxic-
ity, respectively.
Statistical analysis
The results of the statistical analyses were presented as
means ± standard deviation. For comparison of individual
time points, differences between groups were tested by
unpaired Student's t-test. Survival analysis was computed
by the Kaplan-Meier method and compared by the log-
rank test. All p values were two sides, and significant dif-
ference existed if p < 0.05.
Results
Expression of recombinant human endostatin in vitro
LLC cell line was transduced with 100 MOI of Ad-hEndo
or Ad-null. 48 hr later, concentrated cultured supernatants
were collected, mixed with 2× sample buffer, and then
separated on a 12% SDS/PAGE gel. After transferred onto
the PVDF membrane, followed by being incubated with
the primary antibody and second antibody, a distinct
band about 20 KD, corresponding to the volume of
endostatin, was visualized in the Ad-hEndo treated cells,Journal of Experimental & Clinical Cancer Research 2009, 28:31 http://www.jeccr.com/content/28/1/31
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but not in Ad-null transduced and nontransduced cells
(Figure 1).
Combination treatment significantly reduced tumor 
growth and prolonged life span in vivo
7 d after the Lewis lung cancer model was established, the
C57BL/6 mice were randomized to receive administration
with cisplatin, Ad-Endo, cisplatin plus Ad-Endo, Ad-null
or NS (with the last two treatments as the controls). All
mice were monitored every 4 d for changes in tumor
growth. At Day 50, all the mice were sacrificed. Treatment
with cisplatin or Ad-Endo as the single agent resulted in a
19.6% or 38.4% regression of tumor growth and pro-
longed survival time compared with the control groups
(Ad-null or NS). Furthermore, the combination group
showed reduced tumor volume by 69.5% and longer life
span(P < 0.05) (Figure 2).
Inhibition of tumor-induced angiogenesis and increase of 
apoptosis in vivo
Angiogenesis within tumor tissues was estimated in terms
of microvessel density (by counting the number of micro-
vessels) on the section stained with anti-mouse CD31
antibody. The apoptotic tumor cells were determined by
the TUNEL assay. Tumors of the control groups, treated
with Ad-null or NS, showed larger microvessel count than
those of the other groups submitted to cisplatin or/and
Ad-Endo, especially the combination group (P < 0.05)
(Figure 3). There was no difference in apoptotic index
among all groups, but more apoptotic cells were seen in
the group of chemotherapy or adenovirus treatment
alone. Furthermore, the combination group showed the
largest apoptotic index (Figure 4).
Inhibition of angiogenesis in the alginate encapsulation 
assay
We examined the effect of endostatin on angiogenesis in
vivo by the alginate encapsulation assay. Alginate beads
containing lewis lung cancer cells were implanted s.c. on
the back of C57BL/6 mice. Different treatments were per-
formed in recipient mice. 14 d later, alginate implants
containing LLC cells showed strong vascularization in the
group of Ad-null or NS under the stereomicroscope. The
FITC-dextran uptake was 62–77% higher in the group of
Ad-null or NS than in the group of Ad-hEndo alone or in
the combination treatment group and 11% more than in
the group of cisplatin alone (Figure 5).
Toxicity
In the current research, compared with the control groups,
no significant adverse consequences were observed in the
light of gross measures such as weight loss, ruffled fur and
behavior change. Furthermore, no pathologic changes in
heart, liver, lung, spleen, kidney, etc., were found via
microscopic examination(Figure 6).
The white blood cell count, red blood cell count and
platelet count as well as GOT and GPT levels were all in
the normal range. Compared with the control groups,
none of the above parameters of the treatment groups
showed significant difference (Table 1).
Discussion
It is well known that growth and progression of most solid
tumors are angiogenesis dependent. Antiangiogenesis
therapy for cancer can effectively inhibit tumor growth by
inhibiting tumor-associated angiogenesis. When the
tumor is deprived of essential nutrients and oxygen, the
cell proliferation and metastasis is stalled. Endostatin is
one of the potent endogenous angiogenesis inhibitors.
Accumulated evidence suggests that it is a powerful spe-
cific marker of angiogenesis in malignancy of solid tumor.
Although angiogenenic inhibitors can retard tumor
growth through inhibiting angiogenesis, no angiogenesis
associated agent alone or combination with other antitu-
mor agents can eradicate tumor and reach desirable anti-
tumor effects.
Chemotherapeutic agents exert damages to DNA and dis-
rupt DNA replication in cell proliferation. Cisplatin, or
cis-diamminedichloroplatinum (CDDP), as the adduct of
platinum, has been an antineoplastic agent in general use.
It shows similar mechanism as alkylation agent. The plat-
inum-DNA crosslink kills cells in different cell cycles,
inhibits DNA biosynthesis, and suppresses cell division
after chloric ion is disassociated from the complex. Until
now cytotoxic agents are the first-line drugs designated to
kill the maximum tumor cells. However, chemotherapy in
megadose is followed by serious side effects such as nau-
sea, vomiting, hair loss, neurotoxicity and myelosuppres-
sion. In general, the responses in patients are unabiding
with relapses accompanied by acquired resistance to the
cytotoxic drugs in some heterogeneous survival cells
Expression of recombinant human endostatin Figure 1
Expression of recombinant human endostatin. 
Recombinant human endostatin was expressed as a single 
band of appropriate 20 KD in Ad-hEndo transfected LLC 
cells(1), while no band was detected in Ad-null (2) trans-
fected or untreated(3) tumor cells.
20KD 
(1)      (2)      (3)   Journal of Experimental & Clinical Cancer Research 2009, 28:31 http://www.jeccr.com/content/28/1/31
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because of indirect selection of chemotherapeutic drugs.
At present the conventional dosing schedule is applied to
balance the toxicity and efficacy, but the severe side effects
and the ultimate failures remain refractory obstacles to
administration of most chemotherapies. So new
approaches are required to achieve a high therapeutic
response rate.
A conventional dosing chemotherapy calls for episodic
application of a cytotoxic drug, and requires a period of
rest during chemotherapy to let normal cells recover. With
a low rate of replication and cell division (the prolifera-
tion index of endothelial cells in tumor vessels is usually
less than 3%), the tumor-associated endothelial cells are
only weakly damaged in the standard chemotherapy.
Tumor-related angiogenesis can supply essential nutrients
and oxygen for the remaining tumor cells, which makes
tumor relapse possible. Our current research confirmed
that intratumoral injection of recombinant endostatin
adenovirus plus a low dose of cisplatin could evidently
improve antitumor efficacy, including tumor growth sup-
pression, mice survival prolongation, and tumor cell
apoptosis augmentation as well as neovascularization
inhibition as compared with the controls. No serious
adverse effects, such as ruffled fur, cachexia, anorexia,
behavior change or toxic death were found in the combi-
nation group. However, up to now, the exact mechanism
is not clear that how the combined agents induced anti-
tumor efficacy. Two possible mechanisms may get
involved. The first is induction of apoptosis. The antiang-
iogenic agents decrease supply of oxygen and nutrients for
the tumor cells by reducing tumor vascular density, per-
fusion and vascular permeability[12], which leads to
apoptosis of tumor cells and thus reinforces apoptosis
efficacy of cisplatin. However, it is not clear whether the
function of cisplatin in tumors is independent on gene
transfer or is a specific part of adenovirus gene transfer.
The second is antiangiogenesis. Cisplatin has been
reported to influence the process of vascularization and to
cause severe vasculotoxicity[13], which can strengthen the
antiangiogenesis efficacy of endostatin. Low-dose cyto-
toxic treatment and antiangiogenesis therapy interact on
each other. If the endothelial cells are treated by antiang-
iogenesis agents, they will lack certain adhesive contacts
with matrix. Nonadherent endothelial cells are more sus-
ceptible to a cytotoxic agent, resulting in a higher apopto-
sis rate[14]. Meanwhile, the initial impaired angiogenesis
can hamper and delay repair of inflicted dividing cells,
and the increased vessel permeability may lead to
increased tumor exposure to cytotoxic drugs. So tumor
Tumor suppression and survival advantage in C57BL/6 mice bearing LLC Figure 2
Tumor suppression and survival advantage in C57BL/6 mice bearing LLC. Tumor volume(A) and survival curves(B). 
Each group of Mice bearing LLC was s.c. injected intratumorally with corresponding treatment as described in "Methods". 
Treatment with combination of cisplatin and Ad-Endo resulted in the marked inhibition of tumor growth and longer life span(P 
< 0.05).
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cells are more vulnerable to the damage effects of chemo-
therapy, especially when the cytotoxic drug is adminis-
tered at a low dose[15,16]. Therefore, a coordination
approach targeting multiple tumor-associated cell proper-
ties seems to be a promising strategy for marked inhibi-
tion of tumor growth[15,17-19].
In summary, our results in the current research indicate
that the combination of antiangiogenesis gene therapy
with low-dose chemotherapy was more effective to sup-
press tumor growth without obvious toxicity in mice than
either agent alone. The mechanism may in part concern
the increased induction of apoptosis and suppression of
angiogenesis in the combination treatment. To our
knowledge, it is the first time that the combination ther-
apy of recombinant human endostatin adenovirus with
low-dose cisplatin is administered and is found to have
improved inhibitory effects on LLC mice. Therefore, the
current study may lead to further exploration of potential
application of combination strategy in lung cancer ther-
apy. However, the optimum antiangiogenic agent and
chemotherapeutic therapy dose to apply as well as the
application schedule may remain unresolved [20-22].
Further researches are anticipated to choose the superior
therapeutic combination strategy for lung cancer.
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Inhibition of angiogenesis within tumor estimated by CD31 immunohistochemical analysis Figure 3
Inhibition of angiogenesis within tumor estimated by CD31 immunohistochemical analysis. (A) were representa-
tive sections from each group. a: Ad-hEndo+ cisplatin; b: Ad-hEndo; c: cisplatin; d: Ad-null; e: NS. (B) Vessel density was deter-
mined via counting the number of the microvessels per high-power field within hot spot area. Values were expressed as means 
± SE (5 high power fields/slide). Tumors of the combination group showed smaller number of microvessel count than that of 
the other groups submitted to cisplatin or Ad-Endo alone, especially the NS (P < 0.05). a: Ad-hEndo+cisplatin; b: Ad-hEndo; c: 
cisplatin; d: Ad-null; e: NS.
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Detection of apoptosis by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling staining of tumor tissues Figure 4
Detection of apoptosis by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling staining of 
tumor tissues. (A) Sections after treatment were stained with the TUNEL analysis to detect apoptotic cells. (B) Apoptotic 
index was determined by calculating the percentage of apoptotic cells among tumor cells (5 high power fields/slide). The com-
bination group showed the highest apoptotic index. a: Ad-hEndo+ cisplatin; b: Ad-hEndo; c: cisplatin; d: Ad-null; e: NS.
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Inhibition of antiangiogenesis assay by alginate bead in vivo Figure 5
Inhibition of antiangiogenesis assay by alginate bead in vivo. (A) Representative alginate beads from each group. (B) 
FITC-dextran uptake of beads from each group. The combination group showed a significant decrease in vascularization com-
pared with the control groups(P < 0.05). The results were expressed as mean ± S.E. a: Ad-hEndo+ cisplatin; b: Ad-hEndo; c: 
cisplatin; d: Ad-null; e: NS.
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Toxicity observation I Figure 6
Toxicity observation I. H & E staining of heart(a), liver(b), lung (c), spleen(d) and kidney(e) in recipient mice. No hemor-
rhage in organs appeared in the combination group and no differences were seen among groups. A: Ad-hEndo+ cisplatin; B: Ad-
hEndo; C: cisplatin; D: Ad-null; E: NS.
(A) 
(B) 
(D) 
(E) 
(C) 
 
Table 1: Toxicity observation II
Ad-hEndo+ cisplatin Ad-hEndo cisplatin Ad-null NS
White blood cell (×103/mm3) 7.58 ± 2.12 7.89 ± 2.5 7.44 ± 1.98 7.96 ± 2.58 8.02 ± 2.83
Red blood cell (×104/mm3) 701.5 ± 28.5 721.3 ± 22.5 700.4 ± 20.2 756 ± 25.2 780.5 ± 25.5
Platelet (×104/mm3) 30.2 ± 7.5 25 ± 8.2 22.5 ± 6.9 32 ± 8.9 41 ± 7.2
GOT (IU/I) 241.3 ± 26.8 219.6 ± 35.6 252.6 ± 29.7 240.5 ± 39.4 267.5 ± 36.6
GPT (IU/I) 50.2 ± 11.3 43.2 ± 7.5 40.5 ± 7.9 42.8 ± 7.4 45.2 ± 8.4
Mean ± SD of 5 mice in each group. Compared with the control groups(p > 0.05), all treatment groups showed no significant difference. Publish with BioMed Central    and   every 
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